

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Tamiflu (oseltamivir)

Override(s)	Approval Duration
Quantity Limit	One time

Medications	Quantity Limit
Tamiflu (oseltamivir) capsules 30mg	20 per fill; 1 fill per 90 days
Tamiflu (oseltamivir) capsules 45mg	10 per fill; 1 fill per 90 days
Tamiflu (oseltamivir) capsules 75mg	10 per fill; 1 fill per 90 days
Tamiflu (oseltamivir) suspension 6 mg/mL	180 mL per fill; 1 fill per 90 days

APPROVAL CRITERIA

Requests for additional quantity, up to an additional 32 day supply for extended chemoprophylaxis as noted in the chart below, may be approved for the following (ACIP 2019; IDSA, 2018):

- I. Residents in an institutional setting (including long-term care facilities), regardless of vaccination status, will require chemoprophylaxis for 14 days OR for 7 days after the onset of symptoms in the last individual infected, whichever is longer.

Additional quantity allowed if conditions above are met:

Drug	Limit
Tamiflu (oseltamivir) capsules 30mg	64 capsules
Tamiflu (oseltamivir) capsules 45mg	32 capsules
Tamiflu (oseltamivir) capsules 75mg	32 capsules
Tamiflu (oseltamivir) suspension 6 mg/mL	420 mL

State Specific Mandates

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

State name N/A	Date effective N/A	Mandate details (including specific bill if applicable) N/A
-------------------	-----------------------	--

Key References:

1. AAP Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2019-2020. Pediatrics. 2019;144(4): e20192478.
2. Centers for Disease Control (CDC). Seasonal Influenza (Flu). Antiviral Drugs. Influenza Antiviral Medications: Summary for Clinicians. Available at: <https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>. Last updated: December 27, 2018. Accessed: September 4, 2019.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 4, 2019.
4. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices -- United States, 2019-20 Influenza Season. MMWR Recomm Rep 2019;68(No. RR-3):1–21.
5. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clinical Infectious Diseases. 2019;68:e1–e47.